Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer (Q33345828)

26 July 2017

title

Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer (English)

1 reference

26 July 2017

Takashi Hirose

1 reference

26 July 2017

Naoya Horichi

1 reference

26 July 2017

Tohru Ohmori

1 reference

26 July 2017

Takao Shirai

1 reference

26 July 2017

Shinya Sohma

1 reference

26 July 2017

Toshimitsu Yamaoka

1 reference

26 July 2017

Tsukasa Ohnishi

1 reference

26 July 2017

Mitsuru Adachi

1 reference

26 July 2017

language of work or name

1 reference

1 January 2003

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

91-97

1 reference

Gemcitabine: current status of phase I and II trials

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900305-7

7 January 2021

10.1016/S0169-5002(02)00305-7

Identifiers

DOI

1 reference

26 July 2017

1 reference